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Cardiovascular disease (CVD) is the leading cause of death worldwide, 
with an estimated 15 million people dying from ischaemic heart 
disease and stroke in 2015, which represents 26% of all deaths that 
year.[1] CVD disproportionately impacts low- and middle-income 
countries, where ~80% of the global CVD mortality occurs.[1] 
Dyslipidaemia is an important risk factor and a primary driver for 
CVD, and is defined by the presence of suboptimal serum lipid 
levels that portend heightened risk of cardiovascular events. There 
is a paucity of literature on the epidemiology and management of 
dyslipidaemia in South Africa (SA). 
The Health and Aging in Africa: A Longitudinal Study of an 
INDEPTH Community in South Africa (HAALSI) study[2] 
was designed to assess the awareness, treatment and control of 
dyslipidaemia in rural SA, and reported that 67% of rural South 
Africans met criteria for dyslipidaemia; only 30% of them were aware 
of their condition and only 0.7% were receiving treatment. In the 
HAALSI study,[2] being overweight was predictive of dyslipidaemia 
and dyslipidaemia awareness. These data are particularly concerning 
when considered against the background of rising levels of obesity, 
especially among rural women, as well as the increasing vulnerability 
of rural SA populations, who have limited access to both information 
and optimal medical therapy. 
In the Dyslipidemia International Study (DYSIS),[3] a cross-
sectional, observational study of lipid control in patients receiving 
statin therapy, the SA participants >45 years old and who had been 
treated with a stable dose of a statin for 3 years, had lipid goal 
attainment investigated. DYSIS reported that 50% of the SA patients 
did not achieve target low-density lipoprotein cholesterol (LDL-C) 
levels and 74% of these patients were at very high risk of CVD. 
Furthermore, 34% had low high-density lipoprotein cholesterol 
(HDL-C) levels and 45% had elevated triglyceride (TG) levels 
despite statin therapy.[3] Persisting lipid abnormalities in the context 
of suboptimal therapy place patients at ongoing risk of CVD, 
particularly many SA public sector patients who receive very low 
doses of statins, with lipid profiles not followed up after initiation 
of therapy. 
A retrospective study performed on black SA patients treated 
at the Dr George Mukhari Hospital, Gauteng, found a significant 
burden and high prevalence of dyslipidaemia in black adults in 
whom a monogenic disorder should have been considered.[4] Severe 
hypercholesterolaemia (TG >7 mmol/L) was seen in 5% and extreme 
hypercholesterolaemia (TG >12 mmol/L) in 0.5% of patients. Elevated 
TG levels were noted in 9% of patients. The authors concluded 
that the extent and severity of the dyslipidaemia justified a special 
clinic and laboratory to ensure accurate diagnosis, with effective 
intervention for patients and their families.[4] Indeed, there are very 
few dedicated, specialist lipid clinics in the public and private sectors 
in SA.
The association between dyslipidaemia and anthropometric 
indicators in black and white adolescents (aged 12 - 16 years) residing 
in the North West Province of SA has been investigated in the 
Physical Activity and Health Longitudinal (PAHL) study.[5] This study 
found that waist circumference correlated negatively with HDL-C in 
both black and white children, and in white children it also correlated 
positively with LDL-C, total cholesterol (TC)/HDL-C and LDL-C/
HDL-C ratios. In white children, there were greater associations 
between dyslipidaemia and anthropometric indicators, suggesting 
that there might be differences in lipid metabolism or susceptibility 
to risk factors at this young age.[5] These biological risk factors are 
further complicated by lack of physical activity and unhealthy diets 
among young South Africans. 
In the SA population, diabetes is an important driver of 
dyslipidaemia. A publication on lipid levels in black South Africans 
with type 2 diabetes confirmed this association.[6] Diabetes often 
coexists with other cardiovascular risk factors, such as hypertension, 
obesity, smoking, gout and hypercoagulability, all of which 
significantly increase the risk of CVD. SA has the largest population 
of people living with HIV worldwide, who receive antiretroviral 
therapy (ART), and also a significant number of treated HIV-infected 
persons with dyslipidaemia. In a recent publication, Dave et al.[7] 
reported the prevalence of dyslipidaemia to be 90% in ART-naive and 
85% in treated HIV-infected South Africans.
 The SA Dyslipidaemia Guideline Consensus Statement,[8] based 
on the European Society of Cardiology and European Atherosclerosis 
Society guidelines, for the management of dyslipidaemia, was 
published in 2012, under the auspices of the SA Heart Association 
and the Lipid and Atherosclerosis Society of Southern Africa. The 
objective of these simplified guidelines was to promote current best 
management of dyslipidaemia in SA. 
In this issue of CME, Blom[9] provides an excellent review on an 
approach to the patient with elevated TGs. Mild-to-moderate hyper-
triglyceridaemia (TG >1.7 - 10 mmol/L) is an independent cardio vascular 
risk factor, while severe hypertriglyceridaemia (TG >10.0 mmol/L) can 
cause acute pancreatitis. Hypertriglyceridaemia is mostly polygenic. 
Secondary factors, such as uncontrolled diabetes, hypothyroidism, 
alcohol, renal disease and medications, are important in precipitat-
ing or exacerbating hypertriglyceridaemia. Patients with hyper-
triglyceridaemia require cardiovascular risk assessment and are in 
the first instance treated with statins if their cardiovascular risk is 
elevated. Control of secondary factors and lifestyle modifications 
are important in managing residual hypertriglyceridaemia in statin-
treated patients. Severe hypertriglyceridaemia is managed by remov-
ing or controlling secondary factors, by following a very low-fat diet 
and by prescribing a fibrate. 
Brozin and Raal[10] provide a state-of-the-art review on novel 
approaches to lipid-lowering therapy, focusing on new drugs and 
their mechanisms of action. Statins (with or without ezetimibe) 
and fibrates are the current first-line therapy in the management 
of dyslipidaemia. Novel agents include the proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors (that have shown to 
lead to a reduction in CVD morbidity), mipomersen, cholesterol 
ester transfer protein (CETP) inhibitors and bempedoic acid. 
Drugs such as pemfibrate,  angiopoietin-like protein 3 (ANGPTL3) 
inhibitors, apolipoprotein C3 (apo C3) inhibitors and diacylglycerol 
acyltransferase-1 (DGAT 1) inhibitors have shown promising results 
in the management of hypertriglyceridaemia. 
Finally, Rusch et al.[11] provide an up-to-date, pragmatic and 
evidence-based approach to the laboratory investigations in 
lipidology. The conventional lipid profile, comprising fasting TG, 
TC, HDL-C and LDL-C, suffices for screening persons at risk for 
atherosclerosis. Non-fasting samples are gaining in popularity. In 
severe dyslipoproteinaemia, special investigations establish the cause 
of the disease and may allow selection of better treatment. In such 
cases, not only apoprotein concentrations, but also enzyme or cell 
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function, as well as genetic investigations, are relevant; important 
genetic disorders to recognise are familial hypercholesterolaemia, 
dysbetalipoproteinaemia and chylomicronaemia. 
It is my hope that the articles in this CME issue will improve 
the investigation and management of dyslipidaemia in SA, thereby 
reducing the risk of CVD in our population. 
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